Masitinib mesylate is primarily used in the treatment of certain types of cancers and inflammatory diseases. It is notably applied in veterinary medicine for the management of mast cell tumors in dogs, offering a targeted approach to inhibit tumor growth. In human medicine, it is being investigated for its potential in treating conditions such as multiple sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and certain cancers like pancreatic cancer, gastrointestinal stromal tumors (GIST), and systemic mastocytosis. The compound works by selectively inhibiting specific tyrosine kinases, which play a critical role in the proliferation and survival of cancer cells and inflammatory responses. Its application in clinical trials has shown promise in improving patient outcomes by reducing disease progression and symptom severity.